A Phase II Trial: Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Malignancies Involving the Central Nervous System

Trial Profile

A Phase II Trial: Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Malignancies Involving the Central Nervous System

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs DM CHOC PEN (Primary)
  • Indications Brain cancer; Brain metastases; Breast cancer; Lung cancer; Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Dekk-Tec
  • Most Recent Events

    • 05 Apr 2017 Results (n=53) from this and one more study (NCT01048008) presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 05 Apr 2017 Results of this and other trial (see CTP 700052826) presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 21 Jun 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top